Establishment Labs Holdings Expands Women's Health Focus Through Upcoming Investment Conferences
- Establishment Labs will participate in three major investment conferences in November 2024 to enhance its visibility in women's health.
- CEO Juan José Chacón-Quirós and CFO Raj Denhoy will showcase innovations like the Motiva® devices at these events.
- The company emphasizes patient safety and satisfaction through advanced products like the Motiva Flora® tissue expander and Mia Femtech™.
Establishment Labs Expands Presence in Women's Health Technology with Upcoming Conferences
Establishment Labs Holdings Inc., a prominent player in the global medical technology landscape, is poised to enhance its visibility and engagement within the healthcare sector through participation in three significant investment conferences in November 2024. This strategic move is indicative of the company’s commitment to advancing women's health, particularly in breast aesthetics and reconstruction. CEO Juan José Chacón-Quirós and CFO Raj Denhoy are set to represent the company at the 2024 UBS Global Healthcare Conference, where they will highlight the innovations and achievements of Establishment Labs. The presentation, scheduled for November 12, is expected to draw attention to the company’s pioneering products, including the Motiva® devices, which have already made a substantial impact with nearly four million units delivered across 85 countries.
Establishment Labs has carved a niche in the medical technology sector by focusing on patient safety and satisfaction, setting new benchmarks with its advanced offerings. The company’s flagship product, the Motiva Flora® tissue expander, stands out as the only regulatory-approved expander worldwide featuring an integrated port with radio-frequency technology, which enhances its MRI compatibility. This innovation not only underscores Establishment Labs’ commitment to improving surgical outcomes but also reflects its comprehensive understanding of patient needs. Additionally, the launch of Mia Femtech™, a minimally invasive solution aimed at achieving breast harmony, further demonstrates the company’s dedication to innovation in women’s health.
The company's robust intellectual property portfolio, comprising over 200 patent applications across 20 families, and its substantial contribution to scientific research—evidenced by over 100 published studies in peer-reviewed journals—reinforce Establishment Labs' position as a leader in the industry. The operational backbone of the company includes two state-of-the-art manufacturing facilities in Costa Rica that adhere to stringent ISO13485:2016 and FDA regulations under the MDSAP program. This adherence to regulatory standards not only ensures the quality and safety of its products but also enhances the trust of healthcare professionals and patients alike.
In addition to the UBS Global Healthcare Conference, CEO Chacón-Quirós will also address attendees at the 2024 Jefferies London Healthcare Conference on November 20, focusing on the company’s growth and innovations. CFO Denhoy is scheduled to present at the 2024 Stephens Annual Investment Conference on November 21, providing further insights into the company's strategic initiatives. Live webcasts of these presentations will be made available on the Establishment Labs investor relations website, with archived versions accessible post-event, ensuring that stakeholders remain informed about the company’s developments and future directions.